Ajinomoto Bio-Pharma Services
https://ajibio-pharma.com/
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Ajinomoto Bio-Pharma Services
Merck & Co. Buys Out OncoImmune For Phase III COVID-19 Therapy
Deal snapshot: For $425m up front, the pharma obtains a Phase III recombination fusion protein that shows ability to improve hospitalized patients’ clinical status and reduce risk of death.
Slow And Steady: Merck Advances COVID-19 Antiviral, Vaccine Programs
Merck’s third quarter beat analyst consensus and the company raised its guidance. The COVID-19-battered vaccines business began to improve but Gardasil’s recovery was slower than expected.
Finance Watch: One Small Pain Drug Maker And Three Biotech SPACs Launch IPOs
After a brief lull in US initial public offerings, PainReform and three special purpose acquisition companies kicked off September’s IPOs. Also, Immunovant offering grossed $173.9m, Carlyle Group bought 5% stake in China’s Salubris and Erasca increased its series B to $236m.
Merck CEO Stresses Need For ‘Fair Return’ On COVID-19 Interventions
Merck & Co’s chief executive shares views on the need for “reasonable” returns on COVID-19 therapeutics and vaccines, and on the future US pricing environment, at the USAIC summit.
Company Information
- Industry
- Contract Research, Toxicology Testing-CRO
- Pharmaceuticals
- Research, Analytical Equipment & Supplies
- Contract Manufacturing Organization
- Other Names / Subsidiaries
-
- Althea Technologies, Inc.
- Ajinomoto Pharmaceuticals Co., Ltd.
- EA Pharma Co., Ltd.
- GeneDesign
- OmniChem
- Granules OmniChem Private Limited